Aurobindo Pharma Ltd

According to an exchange filing, the US FDA conducted an inspection at Unit-II of Eugia Pharma Specialities, a wholly owned subsidiary of the company, located in the RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan, between 3 November and 14 November 2025. At the conclusion of the inspection, a Form 483 with nine observations was issued. The US FDA has now determined the inspection classification status of the unit as official action indicated (OAI). The company said, 'At this point in time, the company doesn't foresee any impact on the business.' The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25. Shares of Aurobindo Pharma shed 0.54% to Rs 1,280.50 on the BSE. Powered by Capital Market - Live

Securities in F&O Ban: Sammaan Capital and Steel Authority of India shares are banned from F&O trading on 18 March 2026. Stocks to Watch: Aurobindo Pharma announced that the US FDA has concluded an inspection at its arm, Eugia Pharma's Bhiwadi unit with nine observations and classified the inspection as 'Official Action Indicated' (OAI). NHPC announced the commencement of commercial operations for the first 250 MW unit of the Subansiri Lower Hydroelectric Project (SLHP). A B Infrabuild announced that it has receives a Letter of Acceptance for a project valued at Rs 48 crore. Sasken Technologies announced that its board will meet on March 24 to consider various business-related matters. Wipro announced that the company has partnered with Harness to accelerate AI-native software delivery. Ceigall India announced that its arm, Ceigall Infra Projects, has emerged as the L1 bidder for two tenders in Punjab worth Rs 207 crore. Lokesh Machines announced that it has received an order worth Rs 9.50 crore from Directorate General, Sashastra Seema Bal (SSB) Ministry of Home Affairs, Government of India for Supply of latest SMG (9x19mm Carbine), along with accessories. Clean Max Enviro Energy Solutions reported a 1023.98% year-on-year rise in consolidated net profit to Rs 27.65 crore for the quarter ended December 2025, compared to Rs 2.46 crore in the corresponding quarter ended December 2024. The company's sales increased by 13.04% to Rs 422.46 crore in the December 2025 quarter, as against Rs 373.73 crore in the same quarter of the previous year. Powered by Capital Market - Live

The USFDA classified the inspection outcome as 'Voluntary Action Indicated' (VAI) and confirmed that the inspection has been closed. The USFDA had inspected the facility from 8 December to 17 December 2025, following which a Form 483 with five observations was issued at the end of the inspection. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25. Shares of Aurobindo Pharma shed 0.95% to Rs 1,199.85 on the BSE.Powered by Capital Market - Live

Aurobindo Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 1312.7, up 2.08% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 1.03% on the day, quoting at 24010.95. The Sensex is at 77280.41, down 1.18%. Aurobindo Pharma Ltd has added around 13.37% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has added around 4.99% in last one month and is currently quoting at 23253.65, up 1.08% on the day. The volume in the stock stood at 14.65 lakh shares today, compared to the daily average of 17.94 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 1311.6, up 1.56% on the day. Aurobindo Pharma Ltd is up 18.49% in last one year as compared to a 6.86% gain in NIFTY and a 15.08% gain in the Nifty Pharma index.The PE of the stock is 34.84 based on TTM earnings ending December 25.Powered by Capital Market - Live

The product is the generic equivalent of Pomalyst Capsules of BMS Pharmaceuticals Corp. Eugia Pharma Specialities was among the First-to-File (FTF) ANDA applicants. Manufacturing will take place at Eugia Unit-I. Pomalidomide, a third-generation immunomodulatory drug (IMiD), is used in combination with dexamethasone, and sometimes bortezomib, for relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma. According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25. Shares of Aurobindo Pharma shed 0.95% to Rs 1,199.85 on the BSE.Powered by Capital Market - Live

Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, has launched Pomalidomide Capsules, 1 mg, 2 mg, 3 mg and 4 mg, in the US market. The product is the generic equivalent of Pomalyst' Capsules, 1 mg, 2 mg, 3 mg and 4 mg, of BMS Pharmaceuticals Corp. Eugia Pharma Specialities was one of the First-to-File (FTF) ANDA applicants for this product. The product will be manufactured at Eugia Unit-I. According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S. Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone (and sometimes bortezomib) to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.Powered by Capital Market - Live

The facility (Unit-I), located at Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana, was inspected from 16 February to 27 February 2026, and the inspection concluded with four observations. The company said it will respond to the US FDA within the stipulated timelines. The company confirmed there is no impact on its financials or operations due to the inspection. Aurobindo Pharma stated its commitment to maintaining high-quality manufacturing standards across all its facilities worldwide and said it will update the stock exchanges if there is any further information. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25. Shares of Aurobindo Pharma shed 0.04% to end at Rs 1,221.55 on the BSE on Friday.Powered by Capital Market - Live

Aurobindo Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1225.5, up 1.16% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 25452.6. The Sensex is at 82117.03, down 0.19%. Aurobindo Pharma Ltd has risen around 8.48% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 6.36% in last one month and is currently quoting at 23051.85, up 0.53% on the day. The volume in the stock stood at 14.57 lakh shares today, compared to the daily average of 22.48 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 1229.4, up 0.67% on the day. Aurobindo Pharma Ltd is up 13.4% in last one year as compared to a 12.9% spurt in NIFTY and a 14.71% spurt in the Nifty Pharma index.The PE of the stock is 32.89 based on TTM earnings ending December 25.Powered by Capital Market - Live

The approval covers Everolimus tablets in strengths of 0.25 mg, 0.5 mg, 0.75 mg and 1 mg. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zortress Tablets, marketed by Novartis Pharmaceuticals Corp. Everolimus tablets are indicated for the prophylaxis of organ rejection in adult patients undergoing kidney and liver transplants. For kidney transplant patients at low-to-moderate immunologic risk, the drug is used in combination with basiliximab, reduced-dose cyclosporine and corticosteroids. For liver transplant patients, it is administered no earlier than 30 days post-transplant, in combination with reduced-dose tacrolimus and corticosteroids. The approval was granted to Eugia Unit-I, and the product is expected to be launched in the first quarter of FY27. According to IQVIA MAT data for the twelve months ended December 2025, the approved product has an estimated market size of $ 78 million. With this approval, Eugia Pharma Specialities Group has received a total of 184 ANDA approvals, including 10 tentative approvals, across its facilities manufacturing oncology oral and sterile specialty products. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25. Powered by Capital Market - Live

Aurobindo Pharma announced that its wholly owned subsidiary, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Everolimus Tablets, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zortress Tablets, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, of Novartis Pharmaceuticals Corp. This approval has been received from Eugia Unit-I and is expected to be launched in Q1FY27. The approved product has an estimated market size of US$ 78 million for the twelve months ending December 2025, according to IQVIA MAT. This is the 184th ANDA approval (including 10 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products. Everolimus Tablets are Indicated for the prophylaxis of organ rejection in adult patients (i) Kidney Transplant: at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids (ii) Liver Transplant: Administer no earlier than 30 days posttransplant. Use in combination with tacrolimus (reduced doses) and corticosteroids. Powered by Capital Market - Live